We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Aux armes, citoyens!

23 January 2004 By Robert Cyran

The two European drugs companies are squaring up for a scrap, picking advisors and quietly slinging mud. Judging by the slide in Sanofi’s stock price, Aventis looks to have won the first salvo in what could be Europe’s largest drugs merger.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)